Covid-19 roundup: South Korean vaccine to go up against AstraZeneca shot in small Phase III; CDC's ACIP affirms full approval for Pfizer/BioNTech vaccine
SK Bioscience, a South Korean company, and GlaxoSmithKline will test their Covid-19 vaccine candidate against AstraZeneca’s shot in about 4,000 people, the companies said Tuesday.
Shots from Pfizer/BioNTech, Moderna and AstraZeneca are approved in South Korea, and the SK shot is the country’s first domestic candidate, potentially helping not only South Korea, but the rest of Asia’s reliance on shots from the West.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
